GlaxoSmithKline (LON:GSK) share price: what to expect from its Q1 results
CFD trading may not be suitable for everyone and can result in losses that exceed your deposits, so please consider our Risk Disclosure Notice and ensure that you fully understand the risks involved. At the end of what was a very successful 2018, GSK announced it would form a new world-leading consumer healthcare joint venture (JV) with rival Pfizer in a move that will see its combined businesses generate sales of around £9.8 billion. Investors will welcome an update on the JV, which brings together two highly complementary portfolios of consumer health brands, including GSK’s Sensodyne, Voltaren, and Panadol, alongside Pfizer’s Advil, Centrum and Caltrate. Investors will have their eye on what GSK intends to pay in dividends to shareholders for 2019, with the JV allowing them to confirm an 80p a share payout, which its management intends to maintain.